Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
Casal J, Amenedo M, Mel JR, Antón LM, Rodríguez-López R, López-López R, González-Ageitos A, Castellanos J, Constenla M, Tisaire JL. Casal J, et al. Among authors: mel jr. Cancer Chemother Pharmacol. 2007 Oct;60(5):725-32. doi: 10.1007/s00280-007-0418-7. Epub 2007 Feb 2. Cancer Chemother Pharmacol. 2007. PMID: 17273825 Clinical Trial.
Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02).
Vázquez S, Huidobro G, Amenedo M, Fírvida JL, León L, Lázaro M, Grande C, Mel JR, Ramos M, Salgado M, Casal J. Vázquez S, et al. Among authors: mel jr. Anticancer Drugs. 2007 Nov;18(10):1201-6. doi: 10.1097/CAD.0b013e328273bbce. Anticancer Drugs. 2007. PMID: 17893521 Clinical Trial.
A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma.
Rubio JC, Vázquez S, Vázquez F, Amenedo M, Fírvida JL, Mel JR, Huidobro G, Alvarez E, Lázaro M, Alonso G, Fernández I; Galician Group of Lung Cancer (GGCP in the Spanish acronym). Rubio JC, et al. Among authors: mel jr. Cancer Chemother Pharmacol. 2009 Jul;64(2):379-84. doi: 10.1007/s00280-008-0884-6. Epub 2009 Jan 13. Cancer Chemother Pharmacol. 2009. PMID: 19139896 Clinical Trial.
Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer.
Grande C, Quintero G, Candamio S, París Bouzas L, Villanueva MJ, Campos B, Gallardo E, Alvarez E, Casal J, Mel JR; Grupo Gallego de Investigaciones Oncológicas (GGIO). Grande C, et al. Among authors: mel jr. J Geriatr Oncol. 2013 Apr;4(2):114-21. doi: 10.1016/j.jgo.2013.01.001. Epub 2013 Feb 16. J Geriatr Oncol. 2013. PMID: 24071536 Clinical Trial.
Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer.
Vieitez JM, Valladares M, Gracia M, Gonzalez-Barón M, Martín G, Mel JR, Rodríguez R, Constenla M, Gómez Aldavarí JL, Domínguez S, Dorta J, García-Girón C, López R, Sevilla I, Esteban E, Antón LM, Peláez I, López E, Lacave AJ. Vieitez JM, et al. Among authors: mel jr. Lung Cancer. 2003 Jan;39(1):77-84. doi: 10.1016/s0169-5002(02)00387-2. Lung Cancer. 2003. PMID: 12499098 Clinical Trial.
Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer.
Espinosa E, Morales S, Borrega P, Casas A, Madroñal C, Machengs I, Illarramendi JA, Lizón J, Moreno JA, Belón J, Janáriz J, de la Puente M, Checa T, Mel JR, González Barón M. Espinosa E, et al. Among authors: mel jr. Cancer Chemother Pharmacol. 2004 Dec;54(6):546-52. doi: 10.1007/s00280-004-0830-1. Epub 2004 Aug 17. Cancer Chemother Pharmacol. 2004. PMID: 15316749 Clinical Trial.
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
Salvador J, Manso L, de la Haba J, Jaen A, Ciruelos E, de Villena MC, Gil M, Murias A, Galan A, Jara C, Bayo J, Baena JM, Casal J, Mel JR, Blancas I, Sanchez Rvira P. Salvador J, et al. Among authors: mel jr. Clin Transl Oncol. 2015 Feb;17(2):160-6. doi: 10.1007/s12094-014-1210-x. Epub 2014 Aug 14. Clin Transl Oncol. 2015. PMID: 25119930 Clinical Trial.
Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.
Feliu J, Castañón C, Salud A, Mel JR, Escudero P, Pelegrín A, López-Gómez L, Ruiz M, González E, Juárez F, Lizón J, Castro J, González-Barón M; Oncopaz Cooperative Group, Spain. Feliu J, et al. Among authors: mel jr. Br J Cancer. 2005 Nov 28;93(11):1230-5. doi: 10.1038/sj.bjc.6602860. Br J Cancer. 2005. PMID: 16265344 Free PMC article. Clinical Trial.
21 results